コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 arcosine is coupled to the formation of 5,10-methylenetetrahydrofolate.
2 n to tetrahydrofolate, generating N(5),N(10)-methylenetetrahydrofolate.
3 f serine and tetrahydrofolate to glycine and methylenetetrahydrofolate.
4 f serine and tetrahydrofolate to glycine and methylenetetrahydrofolate.
5 f serine and tetrahydrofolate to glycine and methylenetetrahydrofolate.
6 nd (6S)-tetrahydrofolate to glycine and 5,10-methylenetetrahydrofolate.
7 arbon group to tetrahydrofolate to form 5,10-methylenetetrahydrofolate.
8 y complex formation with [32P]FdUMP and 5,10-methylenetetrahydrofolate.
10 relapse risk by potentially increasing 5,10-methylenetetrahydrofolate and dTMP, enhancing DNA synthe
11 unique tRNA methyltransferase using instead methylenetetrahydrofolate and reduced flavin adenine din
12 ts for dTMP biosynthesis in the form of 5,10-methylenetetrahydrofolate, are direct targets of As2O3-i
14 eoxythymidine monophosphate from dUMP, using methylenetetrahydrofolate as carbon donor and NADPH as h
16 hylate sp(2)-hybridized carbon centers using methylenetetrahydrofolate as the source of the appended
17 enabling xanthommatin biosynthesis in a 5,10-methylenetetrahydrofolate auxotroph of the platform soil
18 ed this enzyme regulates the partitioning of methylenetetrahydrofolate between the thymidylate and ho
19 und to be rate-limiting for the oxidation of methylenetetrahydrofolate by kinetic isotope experiments
20 erichia coli catalyzes the reduction of 5,10-methylenetetrahydrofolate (CH(2)-H(4)folate) by NADH via
21 lyze the NAD(P)H-dependent reduction of 5,10-methylenetetrahydrofolate (CH(2)-H(4)folate) to 5-methyl
22 catalyzes the NADH-linked reduction of 5,10-methylenetetrahydrofolate (CH(2)-H(4)folate) to 5-methyl
23 erichia coli catalyzes the reduction of 5,10-methylenetetrahydrofolate (CH(2)-H(4)folate) to 5-methyl
24 tase (MTHFR) catalyzes the reduction of 5,10-methylenetetrahydrofolate (CH(2)-H(4)folate) to 5-methyl
25 e (MTHFR) catalyzes the reduction of N5, N10-methylenetetrahydrofolate (CH(2)-H(4)folate) to N5-methy
26 -90 times higher, while K(m) values for 5,10-methylenetetrahydrofolate (CH(2)H(4)folate) were 1.5-16-
27 able with the wild-type values, but K(m) for methylenetetrahydrofolate (CH(2)H(4)PteGlu) was >10-fold
28 mE binds guanosine-5'-triphosphate (GTP) and methylenetetrahydrofolate (CH(2)THF), while MnmG binds f
30 yces cerevisiae possesses two cytosolic 5,10-methylenetetrahydrofolate (CH2-THF) dehydrogenases that
31 enzyme that catalyzes the oxidation of 5,10-methylenetetrahydrofolate (CH2-THF) in adult mammalian m
32 sm-based inhibitor 5-fluoro-dUMP (FdUMP) and methylenetetrahydrofolate (CH2THF) have been determined
33 tion pathways compete for a limiting pool of methylenetetrahydrofolate cofactors and that thymidylate
34 g covalent thymidylate synthase-5-fluorodUMP-methylenetetrahydrofolate complex; hence, the Asp side c
36 ificance was undertaken through knockdown of methylenetetrahydrofolate dehydrogenase (MTHFD) genes.
37 -phosphogluconate dehydrogenase (6PGDH), and methylenetetrahydrofolate dehydrogenase (MTHFD) may be t
38 -phosphogluconate dehydrogenase (6PGDH), and methylenetetrahydrofolate dehydrogenase (MTHFD) may be t
40 osophila homolog of the trifunctional enzyme methylenetetrahydrofolate dehydrogenase (MTHFD; E.C.1.5.
43 olism associated with mutations in the human methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) gene
45 (Mthfr), adenosyl-homocysteinase (Ahcy), and methylenetetrahydrofolate dehydrogenase 1 (Mthfd1), was
48 hy by rechanneling free mitochondrial ADP to methylenetetrahydrofolate dehydrogenase 1 L (MTHFD1L), a
50 acid receptor gamma in neural tube defects, methylenetetrahydrofolate dehydrogenase 1 was identified
52 We found that an enzyme in the folate cycle, methylenetetrahydrofolate dehydrogenase 1-like (MTHFD1L)
54 ondrial tetrahydrofolate (mTHF) cycle enzyme methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) being
56 erine hydroxymethyltransferase-2 (SHMT2) and methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) is as
57 w that the one-carbon (1C) metabolism enzyme methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) regul
58 ic transformation is MTHFD2, a mitochondrial methylenetetrahydrofolate dehydrogenase and cyclohydrola
59 amide ribonucleotide formyltransferase, 5,10-methylenetetrahydrofolate dehydrogenase, and 10-formylte
60 onverge on the folate pathway enzyme MTHFD1 (methylenetetrahydrofolate dehydrogenase, cyclohydrolase
61 genetic dependencies caused by mutations in methylenetetrahydrofolate dehydrogenase, cyclohydrolase,
62 production through the reaction catalyzed by methylenetetrahydrofolate dehydrogenase, thus allowing p
63 ymorphisms in flavin monooxygenase-3 (FMO3), methylenetetrahydrofolate dehydrogenase-1 (MTHFD1), fatt
64 sociation in premenopausal women of the 5,10-methylenetetrahydrofolate dehydrogenase-1958A gene allel
65 ls who were carriers of the very common 5,10-methylenetetrahydrofolate dehydrogenase-1958A gene allel
66 The one-carbon folate pathway, specifically methylenetetrahydrofolate dehydrogenase-cyclohydrolase 2
67 ommon polymorphisms in folate genes, such as methylenetetrahydrofolate dehydrogenase-methenyltetrahyd
68 e (WT)], MTR reductase (MTRR) rs1801394, and methylenetetrahydrofolate dehydrogenase-methenyltetrahyd
72 de phosphate-dependent, trifunctional enzyme methylenetetrahydrofolate dehydrogenase/methenyltetrahyd
73 tion (R175Q) in the cytoplasmic bifunctional methylenetetrahydrofolate dehydrogenase/methenyltetrahyd
74 ydroxymethyltransferase (SHMT) generate 5,10-methylenetetrahydrofolate for de novo dTMP biosynthesis
76 ogenase 1 (MTHFD1), an enzyme that generates methylenetetrahydrofolate from formate, ATP, and NADPH,
77 zyme methylenetetrahydrofolate reductase for methylenetetrahydrofolate in a glycine-dependent manner,
80 s the oxidation of methyltetrahydrofolate to methylenetetrahydrofolate in the presence of menadione,
81 ovalerate and (ii) deuterium exchange in the methylenetetrahydrofolate-independent enolization of alp
83 evious metabolic studies that indicated 5,10-methylenetetrahydrofolate is preferentially directed tow
84 olon cancer risk, perhaps by increasing 5,10-methylenetetrahydrofolate levels for DNA synthesis, but
85 ancer probably because higher levels of 5,10-methylenetetrahydrofolate may prevent imbalances of nucl
88 or thymidylate biosynthesis, (2) it depletes methylenetetrahydrofolate pools for SAM synthesis by syn
89 amide ribonucleotide transformylase (347GG), methylenetetrahydrofolate reductase (1298AC/CC), methion
90 strain of Escherichia coli that overproduces methylenetetrahydrofolate reductase (MetF) has been cons
91 l6, IVS6 -68C>T, 1122A>G, and 1053C>T); 5,10-methylenetetrahydrofolate reductase (MTHFR 677C>T and 12
92 tatus, DNA methylation, and polymorphisms of methylenetetrahydrofolate reductase (MTHFR 677C-->T and
93 morphic genes involved in folate metabolism--methylenetetrahydrofolate reductase (MTHFR C677T and A12
94 on mutation (C677T) in the gene encoding for methylenetetrahydrofolate reductase (MTHFR) (5-methyltet
97 of a key one-carbon metabolizing gene [i.e., methylenetetrahydrofolate reductase (MTHFR) 677C>T and 1
99 em for 2 polymorphisms with effects on 1-CM, methylenetetrahydrofolate reductase (MTHFR) 677C>T, rs18
100 genes coding for folate pathway enzymes 5,10-methylenetetrahydrofolate reductase (MTHFR) 677C-->T and
101 the combined effects of the TC 776C-->G and methylenetetrahydrofolate reductase (MTHFR) 677C-->T pol
104 n capability is demonstrated by analyzing 96 methylenetetrahydrofolate reductase (MTHFR) alleles in p
105 Four fetal genetic variants of the 5,10-methylenetetrahydrofolate reductase (MTHFR) and dihydrof
106 at either of two folate metabolism enzymes, methylenetetrahydrofolate reductase (MTHFR) and methioni
108 The single nucleotide polymorphism (SNP) methylenetetrahydrofolate reductase (MTHFR) C677T (rs180
122 treatment on outcome in patients with severe methylenetetrahydrofolate reductase (MTHFR) deficiency i
123 d families, each with 2 siblings with severe methylenetetrahydrofolate reductase (MTHFR) deficiency m
126 estigated whether a polymorphism in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene (C677T)
127 ariant form (the C677T genotype) of the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene and ris
128 ly reported that 2 polymorphisms in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene at posi
130 ozygosity for the variant 677T allele in the methylenetetrahydrofolate reductase (MTHFR) gene increas
131 etermine whether the C677T transition in the methylenetetrahydrofolate reductase (MTHFR) gene is asso
133 ions in cystathionine beta-synthase (CBS) or methylenetetrahydrofolate reductase (MTHFR) gene lead to
134 abolism and the 677C-->T polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene may be
135 at nucleotide 677 (677C-->T) mutation of the methylenetetrahydrofolate reductase (MTHFR) gene may be
137 p of a common polymorphism (667C-->T) of the methylenetetrahydrofolate reductase (MTHFR) gene with th
138 hol intake and 2 common polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene, 677C--
139 is illustrated here using the example of the methylenetetrahydrofolate reductase (MTHFR) gene, homocy
140 ssociation between polymorphisms in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene, includ
141 ion of chromosome 1 that contains a putative methylenetetrahydrofolate reductase (MTHFR) gene, which
145 of 30 men varying in age, fertility status, methylenetetrahydrofolate reductase (MTHFR) genotype, an
146 0 mother-child dyads in association with the methylenetetrahydrofolate reductase (MTHFR) genotype.
147 risk factors, C-reactive protein (CRP), and methylenetetrahydrofolate reductase (MTHFR) genotype.
149 e induced by deficiency in a key OCM enzyme, methylenetetrahydrofolate reductase (MTHFR) in Mthfr(+/-
158 her homocysteine or MTX toxicity differed by methylenetetrahydrofolate reductase (MTHFR) or reduced f
163 ions in cystathionine beta-synthase (Cbs) or methylenetetrahydrofolate reductase (Mthfr) results in n
168 with hypertension and stroke, independent of methylenetetrahydrofolate reductase (MTHFR) variants.
169 ymorphism (TT genotype) in the gene encoding methylenetetrahydrofolate reductase (MTHFR) was responsi
170 AS1-VNTR; OR = 2.50, 95% CI: 1.54-4.05); and methylenetetrahydrofolate reductase (MTHFR)(Val/Val) (OR
173 (Mat1a), cystathionine-beta-synthase (Cbs), methylenetetrahydrofolate reductase (Mthfr), adenosyl-ho
175 n B(12) exposure, the activity of the enzyme methylenetetrahydrofolate reductase (MTHFR), and epigene
176 on of polymorphisms in thymidylate synthase, methylenetetrahydrofolate reductase (MTHFR), and VEGF.
178 of a prototypical vitamin-dependent enzyme, methylenetetrahydrofolate reductase (MTHFR), from 564 in
179 combination, decreased transcript levels of methylenetetrahydrofolate reductase (MTHFR), methionine
180 several B vitamin-dependent enzymes, such as methylenetetrahydrofolate reductase (MTHFR), methionine
182 in the following folate-metabolizing genes: methylenetetrahydrofolate reductase (MTHFR), reduced fol
183 in the methionine synthase reductase (MTRR), methylenetetrahydrofolate reductase (MTHFR), serine hydr
189 interact with common pathogenic variants in methylenetetrahydrofolate reductase (MTHFR); the most pr
190 The presence of a nonsynonymous SNP in the methylenetetrahydrofolate reductase (MTHFR)gene was asso
192 e thermolabile mutation (TT genotype) of the methylenetetrahydrofolate reductase (MTHFR; EC 1.5.1.20)
195 D1 G870A (AA) polymorphism (P = 0.0138), and methylenetetrahydrofolate reductase (NAD(P)H) C677T (TT)
196 the cyclin D1 G870A (AA) polymorphism or the methylenetetrahydrofolate reductase (NAD(P)H) C677T (TT)
197 bstitution at nucleo-tide 677 (677C-->T)] in methylenetetrahydrofolate reductase (NADPH) and the cofa
198 s low: choline dehydrogenase (CHDH) rs12676, methylenetetrahydrofolate reductase 1 (MTHFD1) rs2236225
199 factor V 1691A (Leiden), factor II 20 210A, methylenetetrahydrofolate reductase 667T, type 1 plasmin
200 splant body mass index >or= 25, or carry the methylenetetrahydrofolate reductase 677 TT genotype shou
201 oning regimens, body mass index >or= 25, and methylenetetrahydrofolate reductase 677 TT genotype were
202 mes involved in homocysteine metabolism (ie, methylenetetrahydrofolate reductase [MTHFR] 677C>T and 1
203 onine) and related gene polymorphisms (C677T methylenetetrahydrofolate reductase [MTHFR] and C1420T c
204 perhomocysteinemia secondary to mutations in methylenetetrahydrofolate reductase and cystathionine be
206 R506G, factor II (prothrombin) G20210A, and methylenetetrahydrofolate reductase C677T, compared with
207 Other genetic variants (prothrombin 20210A, methylenetetrahydrofolate reductase C677T, factor XIII V
209 ed serine synthesis competes with the enzyme methylenetetrahydrofolate reductase for methylenetetrahy
211 ene (Factor V Leiden), a variant in the 5,10-methylenetetrahydrofolate reductase gene (MTHFR), and an
213 e +/+ genotype for the C677T mutation in the methylenetetrahydrofolate reductase gene have no increas
214 of the common C677T base substitution in the methylenetetrahydrofolate reductase gene in 110 DNA samp
215 iation of CHD with the C677T mutation of the methylenetetrahydrofolate reductase gene or with 3 mutat
219 iffer from those of the ferredoxin-dependent methylenetetrahydrofolate reductase isolated from the ho
220 mouse models of homocystinuria due to either methylenetetrahydrofolate reductase or Met synthase defi
222 igned to usual care or GERA, which evaluated methylenetetrahydrofolate reductase polymorphisms and se
224 which acts as an allosteric inhibitor of the methylenetetrahydrofolate reductase reaction and as an a
225 ual disease (hazard ratio 7.3; P < .001) and methylenetetrahydrofolate reductase rs1801131 (hazard ra
226 pathway (i.e. folate or B12 deficiencies or methylenetetrahydrofolate reductase thermolability).
227 cumulate via inactivating mutations in metF (methylenetetrahydrofolate reductase) and luxR (the maste
229 point mutation (C677T) in the gene encoding methylenetetrahydrofolate reductase, an enzyme involved
230 , hemoglobin S, the thermolabile mutation of methylenetetrahydrofolate reductase, and the cystic fibr
231 ystathionine-gamma-lyase, paraxonase 1, 5,10-methylenetetrahydrofolate reductase, betaine:homocystein
232 receptors; and vascular redox determinants (methylenetetrahydrofolate reductase, endothelial nitric
233 brinogen, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase, glycoprotein Illa,
234 deficiencies in cystathionine beta synthase, methylenetetrahydrofolate reductase, or in enzymes invol
238 (<301 microg/d) of folate, the substrate for methylenetetrahydrofolate reductase; low intake (<1.8 mg
239 (<1.8 mg/d) of vitamin B2, the cofactor for methylenetetrahydrofolate reductase; low intake (<8.0 mi
242 ase (MTHFR) catalyzes the conversion of 5,10-methylenetetrahydrofolate, required for purine and thymi
243 folate; (2) chemical reduction of liver 5,10-methylenetetrahydrofolate (stabilized at pH 10) to 5-met
245 ) catalyzes the reversible oxidation of 5,10-methylenetetrahydrofolate to 5,10-methenyltetrahydrofola
246 plication by blocking the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate by
247 tase (MTHFR) catalyzes the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, t
248 tase (MTHFR) catalyzes the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, u
249 EC 1.5.1.20) catalyzes the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate.
250 ine hydroxymethyltransferase (cSHMT)-derived methylenetetrahydrofolate to de novo thymidylate biosynt
252 reductase (MTHFR) catalyzes the reduction of methylenetetrahydrofolate to methyltetrahydrofolate, the
253 eductase (MTHFR) catalyzes the conversion of methylenetetrahydrofolate to methyltetrahydrofolate, the
254 e purified enzyme catalyzes the reduction of methylenetetrahydrofolate to methyltetrahydrofolate, usi
255 methyl cycles, catalyzing the conversion of methylenetetrahydrofolate to methyltetrahydrofolate.
256 rahydrofolate reductase (MTHFR) directs 5,10-methylenetetrahydrofolate toward methionine synthesis at